Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients.

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients.

Tegumentary Leishmaniasis (TL) is a neglected, non-contagious, infectious disease, caused by different protozoa species of the Leishmania genus that affects skin and mucous membranes. Meglumine Antimoniate (MA), the first drug of choice for TL treatment in Brazil, has already been associated with co...

Full description

Bibliographic Details
Main Authors:	Débora Cristina de Oliveira Bezerra, Renata Oliveira de Barcelos, Ellen Carvalho de Castro, Claudia Cristina Jardim Duarte, Raquel de Vasconcellos Carvalhaes Oliveira, Tania Salgado de Sousa Torraca, Maria Helena de Araújo-Melo, Frederico Pereira Bom Braga, Benivaldo Ramos Ferreira Terceiro, Lúcia Regina do Nascimento Brahim Paes, Armando de Oliveira Schubach, Cláudia Maria Valete-Rosalino
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5207536?pdf=render

Similar Items

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
by: Cláudia Maria Valete-Rosalino, et al.
Published: (2014-09-01)

Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
by: Maria Cristina de Oliveira Duque, et al.

Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions
by: Jamyra Iglesias Cataldo, et al.

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
by: Erica de Camargo Ferreira e Vasconcellos, et al.
Published: (2014-07-01)

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
by: Lucia Regina Brahim, et al.

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Madelon Novato Ribeiro, et al.
Published: (2014-07-01)

Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study
by: Gagini Thalita, et al.
Published: (2017-01-01)

American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report
by: Maria Inês Fernandes Pimentel, et al.
Published: (2011-04-01)

Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
by: Maria Inês Fernandes Pimentel, et al.

STUDIES ON THE BEHAVIOR OF MEGLUMINE ANTIMONIATE IN THE HUMAN BODY IN RHESUS MONKEYS
by: FLAVIA DE ALMEIDA VIEIRA
Published: (2008)

Oral manifestations in the American tegumentary leishmaniasis.
by: Daniel Cesar Silva da Costa, et al.
Published: (2014-01-01)

In Vitro antileishmanial properties of neutron-irradiated meglumine antimoniate
by: Samanta Etel Treiger Borborema, et al.
Published: (2005-10-01)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Marcelo Rosandiski LYRA, et al.

[en] STUDIES ON THE BEHAVIOR OF MEGLUMINE ANTIMONIATE IN THE HUMAN BODY IN RHESUS MONKEYS
by: FLAVIA DE ALMEIDA VIEIRA
Published: (2008)

Speciation of antimony (III) and antimony (V) using hydride generation for meglumine antimoniate pharmaceutical formulationsquality control
by: Lúcio Mendes Cabral, et al.
Published: (2008-03-01)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
by: Deninson Alejandro Vargas, et al.
Published: (2019-06-01)

Novel methods for the encapsulation of meglumine antimoniate into liposomes
by: F. Frézard, et al.
Published: (2000-07-01)

In Vitro Sensitivity of Paired Leishmania (Viannia) braziliensis Samples Isolated before Meglumine Antimoniate Treatment and after Treatment Failure or Reactivation of Cutaneous Leishmaniasis
by: Cibele Baptista, et al.
Published: (2015-01-01)

Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis
by: Lambertucci José Roberto, et al.
Published: (2004-01-01)

Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate
by: Deise Riba Coelho, et al.
Published: (2014-07-01)

Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report
by: Benivaldo Ramos Ferreira Terceiro, et al.
Published: (2019-01-01)

Effects of Meglumine Antimoniate Treatment on Cytokine Production in a Patient with Mucosal Leishmaniasis and Chagas Diseases Co-Infection
by: Karine Rezende-Oliveira, et al.
Published: (2020-05-01)

Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate
by: Atkinson, S., et al.
Published: (2021)

A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis
by: Raimunda Nonata Ribeiro Sampaio, et al.
Published: (2019-03-01)

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
by: Samanta Etel Treiger Borborema, et al.
Published: (2019-03-01)

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate
by: Olga Lucía Fernández, et al.
Published: (2021-09-01)

ELECTROCARDIOGRAPHIC CHANGES WITH STANDARD DOSE OF MEGLUMINE ANTIMONIATE THERAPY IN CUTANEOUS LEISHMANIASIS
by: Moizza Tahir, et al.
Published: (2021-08-01)

COMPARISON OF ORAL CHLOROQUINE WITH SYSTEMIC MEGLUMINE ANTIMONIATE IN TREATMENT OF CUTANEOUS LEISHMANIASIS
by: Muhammad Farooq, et al.
Published: (2021-02-01)

High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls
by: Gustavo Adolfo Sierra Romero, et al.
Published: (2003-01-01)

Evaluation of polymerase chain reaction in the routine diagnosis for tegumentary leishmaniasis in a referral centre
by: Aline Fagundes, et al.
Published: (2010-02-01)

Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice
by: Samanta Etel Treiger Borborema, et al.
Published: (2013-08-01)

Evoked otoacoustic emissions in workers exposed to noise: A review
by: Alcarás, Patrícia Arruda de Souza, et al.
Published: (2012-01-01)

Evoked otoacoustic emissions in workers exposed to noise: A review
by: Patrícia Arruda de Souza Alcarás, et al.
Published: (2012-10-01)

Evidence for Tissue Toxicity in BALB/c Exposed to a Long-Term Treatment with Oxiranes Compared to Meglumine Antimoniate
by: Luiz Filipe Gonçalves Oliveira, et al.
Published: (2017-01-01)

Voice disorders in mucosal leishmaniasis.
by: Ana Cristina Nunes Ruas, et al.
Published: (2014-01-01)

Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
by: Margarita Arboleda, et al.
Published: (2019-05-01)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
by: Mohamad Javad Yazdanpanah, et al.
Published: (2011-01-01)

Geospatial analysis of tegumentary leishmaniasis in Rio de Janeiro state, Brazil from 2000 to 2015: Species typing and flow of travelers and migrants with leishmaniasis.
by: Luciana de Freitas Campos Miranda, et al.
Published: (2019-11-01)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019-11-01)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
by: Nayara C Brito, et al.
Published: (2019-12-01)